February 27, 2019
Fiscal 2018:
- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Investor News
February 27, 2019
Not intended for U.S. and UK Media
Bayer completes rolling submission for darolutamide in U.S.
moreFebruary 15, 2019
Not intended for U.S. and UK Media
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
moreFebruary 14, 2019
Not intended for U.S. and UK Media - American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019
Bayer's darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
moreJanuary 08, 2019
New predictive seed placement technology delivers strong results in 2018: